Global Anti-Dermatomycosis Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 101

Published Date: 16 May 2022

Category: Medical Devices & Consumables

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Product Tags

Description

The Anti-Dermatomycosis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Anti-Dermatomycosis Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Tinea Corporis accounting for % of the Anti-Dermatomycosis Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Polyens segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Anti-Dermatomycosis Treatment include Pfizer Inc., Sanofi S.A., Novatis AG, Mylan N.V., and Abbott Laboratories, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation
Anti-Dermatomycosis Treatment market is split by Drug Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Drug Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Drug Type, covers
Polyens
Azoles
Allylamines
Echinocandins
Others

Market segment by Application, can be divided into
Tinea Corporis
Tinea Unguium
Aspergillosis
Tinea Capitis
Others

Market segment by players, this report covers
Pfizer Inc.
Sanofi S.A.
Novatis AG
Mylan N.V.
Abbott Laboratories
Bayer AG
Scynexis Inc.
Glaxosmithkline Plc
Enzon Pharmaceuticals
Gilead Sciences Inc.
Astellas Pharma Inc.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Anti-Dermatomycosis Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Anti-Dermatomycosis Treatment, with revenue, gross margin and global market share of Anti-Dermatomycosis Treatment from 2019 to 2022.
Chapter 3, the Anti-Dermatomycosis Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Drug Type and application, with revenue and growth rate by Drug Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Anti-Dermatomycosis Treatment market forecast, by regions, drug type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Anti-Dermatomycosis Treatment research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Anti-Dermatomycosis Treatment
    1.2 Classification of Anti-Dermatomycosis Treatment by Drug Type
        1.2.1 Overview: Global Anti-Dermatomycosis Treatment Market Size by Drug Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Anti-Dermatomycosis Treatment Revenue Market Share by Drug Type in 2021
        1.2.3 Polyens
        1.2.4 Azoles
        1.2.5 Allylamines
        1.2.6 Echinocandins
        1.2.7 Others
    1.3 Global Anti-Dermatomycosis Treatment Market by Application
        1.3.1 Overview: Global Anti-Dermatomycosis Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Tinea Corporis
        1.3.3 Tinea Unguium
        1.3.4 Aspergillosis
        1.3.5 Tinea Capitis
        1.3.6 Others
    1.4 Global Anti-Dermatomycosis Treatment Market Size & Forecast
    1.5 Global Anti-Dermatomycosis Treatment Market Size and Forecast by Region
        1.5.1 Global Anti-Dermatomycosis Treatment Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Anti-Dermatomycosis Treatment Market Size by Region, (2017-2022)
        1.5.3 North America Anti-Dermatomycosis Treatment Market Size and Prospect (2017-2028)
        1.5.4 Europe Anti-Dermatomycosis Treatment Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Anti-Dermatomycosis Treatment Market Size and Prospect (2017-2028)
        1.5.6 South America Anti-Dermatomycosis Treatment Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Anti-Dermatomycosis Treatment Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Anti-Dermatomycosis Treatment Market Drivers
        1.6.2 Anti-Dermatomycosis Treatment Market Restraints
        1.6.3 Anti-Dermatomycosis Treatment Trends Analysis

2 Company Profiles
    2.1 Pfizer Inc.
        2.1.1 Pfizer Inc. Details
        2.1.2 Pfizer Inc. Major Business
        2.1.3 Pfizer Inc. Anti-Dermatomycosis Treatment Product and Solutions
        2.1.4 Pfizer Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 Pfizer Inc. Recent Developments and Future Plans
    2.2 Sanofi S.A.
        2.2.1 Sanofi S.A. Details
        2.2.2 Sanofi S.A. Major Business
        2.2.3 Sanofi S.A. Anti-Dermatomycosis Treatment Product and Solutions
        2.2.4 Sanofi S.A. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Sanofi S.A. Recent Developments and Future Plans
    2.3 Novatis AG
        2.3.1 Novatis AG Details
        2.3.2 Novatis AG Major Business
        2.3.3 Novatis AG Anti-Dermatomycosis Treatment Product and Solutions
        2.3.4 Novatis AG Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 Novatis AG Recent Developments and Future Plans
    2.4 Mylan N.V.
        2.4.1 Mylan N.V. Details
        2.4.2 Mylan N.V. Major Business
        2.4.3 Mylan N.V. Anti-Dermatomycosis Treatment Product and Solutions
        2.4.4 Mylan N.V. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Mylan N.V. Recent Developments and Future Plans
    2.5 Abbott Laboratories
        2.5.1 Abbott Laboratories Details
        2.5.2 Abbott Laboratories Major Business
        2.5.3 Abbott Laboratories Anti-Dermatomycosis Treatment Product and Solutions
        2.5.4 Abbott Laboratories Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Abbott Laboratories Recent Developments and Future Plans
    2.6 Bayer AG
        2.6.1 Bayer AG Details
        2.6.2 Bayer AG Major Business
        2.6.3 Bayer AG Anti-Dermatomycosis Treatment Product and Solutions
        2.6.4 Bayer AG Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Bayer AG Recent Developments and Future Plans
    2.7 Scynexis Inc.
        2.7.1 Scynexis Inc. Details
        2.7.2 Scynexis Inc. Major Business
        2.7.3 Scynexis Inc. Anti-Dermatomycosis Treatment Product and Solutions
        2.7.4 Scynexis Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Scynexis Inc. Recent Developments and Future Plans
    2.8 Glaxosmithkline Plc
        2.8.1 Glaxosmithkline Plc Details
        2.8.2 Glaxosmithkline Plc Major Business
        2.8.3 Glaxosmithkline Plc Anti-Dermatomycosis Treatment Product and Solutions
        2.8.4 Glaxosmithkline Plc Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Glaxosmithkline Plc Recent Developments and Future Plans
    2.9 Enzon Pharmaceuticals
        2.9.1 Enzon Pharmaceuticals Details
        2.9.2 Enzon Pharmaceuticals Major Business
        2.9.3 Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Product and Solutions
        2.9.4 Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 Enzon Pharmaceuticals Recent Developments and Future Plans
    2.10 Gilead Sciences Inc.
        2.10.1 Gilead Sciences Inc. Details
        2.10.2 Gilead Sciences Inc. Major Business
        2.10.3 Gilead Sciences Inc. Anti-Dermatomycosis Treatment Product and Solutions
        2.10.4 Gilead Sciences Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 Gilead Sciences Inc. Recent Developments and Future Plans
    2.11 Astellas Pharma Inc.
        2.11.1 Astellas Pharma Inc. Details
        2.11.2 Astellas Pharma Inc. Major Business
        2.11.3 Astellas Pharma Inc. Anti-Dermatomycosis Treatment Product and Solutions
        2.11.4 Astellas Pharma Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 Astellas Pharma Inc. Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Anti-Dermatomycosis Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Anti-Dermatomycosis Treatment Players Market Share in 2021
        3.2.2 Top 10 Anti-Dermatomycosis Treatment Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Anti-Dermatomycosis Treatment Players Head Office, Products and Services Provided
    3.4 Anti-Dermatomycosis Treatment Mergers & Acquisitions
    3.5 Anti-Dermatomycosis Treatment New Entrants and Expansion Plans

4 Market Size Segment by Drug Type
    4.1 Global Anti-Dermatomycosis Treatment Revenue and Market Share by Drug Type (2017-2022)
    4.2 Global Anti-Dermatomycosis Treatment Market Forecast by Drug Type (2023-2028)

5 Market Size Segment by Application
    5.1 Global Anti-Dermatomycosis Treatment Revenue Market Share by Application (2017-2022)
    5.2 Global Anti-Dermatomycosis Treatment Market Forecast by Application (2023-2028)

6 North America by Country, by Drug Type, and by Application
    6.1 North America Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2028)
    6.2 North America Anti-Dermatomycosis Treatment Revenue by Application (2017-2028)
    6.3 North America Anti-Dermatomycosis Treatment Market Size by Country
        6.3.1 North America Anti-Dermatomycosis Treatment Revenue by Country (2017-2028)
        6.3.2 United States Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        6.3.3 Canada Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        6.3.4 Mexico Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)

7 Europe by Country, by Drug Type, and by Application
    7.1 Europe Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2028)
    7.2 Europe Anti-Dermatomycosis Treatment Revenue by Application (2017-2028)
    7.3 Europe Anti-Dermatomycosis Treatment Market Size by Country
        7.3.1 Europe Anti-Dermatomycosis Treatment Revenue by Country (2017-2028)
        7.3.2 Germany Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        7.3.3 France Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        7.3.5 Russia Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        7.3.6 Italy Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Drug Type, and by Application
    8.1 Asia-Pacific Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2028)
    8.2 Asia-Pacific Anti-Dermatomycosis Treatment Revenue by Application (2017-2028)
    8.3 Asia-Pacific Anti-Dermatomycosis Treatment Market Size by Region
        8.3.1 Asia-Pacific Anti-Dermatomycosis Treatment Revenue by Region (2017-2028)
        8.3.2 China Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        8.3.3 Japan Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        8.3.4 South Korea Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        8.3.5 India Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        8.3.7 Australia Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)

9 South America by Country, by Drug Type, and by Application
    9.1 South America Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2028)
    9.2 South America Anti-Dermatomycosis Treatment Revenue by Application (2017-2028)
    9.3 South America Anti-Dermatomycosis Treatment Market Size by Country
        9.3.1 South America Anti-Dermatomycosis Treatment Revenue by Country (2017-2028)
        9.3.2 Brazil Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        9.3.3 Argentina Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Drug Type, and by Application
    10.1 Middle East & Africa Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2028)
    10.2 Middle East & Africa Anti-Dermatomycosis Treatment Revenue by Application (2017-2028)
    10.3 Middle East & Africa Anti-Dermatomycosis Treatment Market Size by Country
        10.3.1 Middle East & Africa Anti-Dermatomycosis Treatment Revenue by Country (2017-2028)
        10.3.2 Turkey Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)
        10.3.4 UAE Anti-Dermatomycosis Treatment Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Anti-Dermatomycosis Treatment Revenue by Drug Type, (USD Million), 2017 VS 2021 VS 2028
    Table 2. Global Anti-Dermatomycosis Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
    Table 3. Global Market Anti-Dermatomycosis Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
    Table 4. Global Anti-Dermatomycosis Treatment Revenue (USD Million) by Region (2017-2022)
    Table 5. Global Anti-Dermatomycosis Treatment Revenue Market Share by Region (2023-2028)
    Table 6. Pfizer Inc. Corporate Information, Head Office, and Major Competitors
    Table 7. Pfizer Inc. Major Business
    Table 8. Pfizer Inc. Anti-Dermatomycosis Treatment Product and Solutions
    Table 9. Pfizer Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 10. Sanofi S.A. Corporate Information, Head Office, and Major Competitors
    Table 11. Sanofi S.A. Major Business
    Table 12. Sanofi S.A. Anti-Dermatomycosis Treatment Product and Solutions
    Table 13. Sanofi S.A. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 14. Novatis AG Corporate Information, Head Office, and Major Competitors
    Table 15. Novatis AG Major Business
    Table 16. Novatis AG Anti-Dermatomycosis Treatment Product and Solutions
    Table 17. Novatis AG Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 18. Mylan N.V. Corporate Information, Head Office, and Major Competitors
    Table 19. Mylan N.V. Major Business
    Table 20. Mylan N.V. Anti-Dermatomycosis Treatment Product and Solutions
    Table 21. Mylan N.V. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 22. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
    Table 23. Abbott Laboratories Major Business
    Table 24. Abbott Laboratories Anti-Dermatomycosis Treatment Product and Solutions
    Table 25. Abbott Laboratories Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 26. Bayer AG Corporate Information, Head Office, and Major Competitors
    Table 27. Bayer AG Major Business
    Table 28. Bayer AG Anti-Dermatomycosis Treatment Product and Solutions
    Table 29. Bayer AG Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 30. Scynexis Inc. Corporate Information, Head Office, and Major Competitors
    Table 31. Scynexis Inc. Major Business
    Table 32. Scynexis Inc. Anti-Dermatomycosis Treatment Product and Solutions
    Table 33. Scynexis Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 34. Glaxosmithkline Plc Corporate Information, Head Office, and Major Competitors
    Table 35. Glaxosmithkline Plc Major Business
    Table 36. Glaxosmithkline Plc Anti-Dermatomycosis Treatment Product and Solutions
    Table 37. Glaxosmithkline Plc Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 38. Enzon Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 39. Enzon Pharmaceuticals Major Business
    Table 40. Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Product and Solutions
    Table 41. Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 42. Gilead Sciences Inc. Corporate Information, Head Office, and Major Competitors
    Table 43. Gilead Sciences Inc. Major Business
    Table 44. Gilead Sciences Inc. Anti-Dermatomycosis Treatment Product and Solutions
    Table 45. Gilead Sciences Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 46. Astellas Pharma Inc. Corporate Information, Head Office, and Major Competitors
    Table 47. Astellas Pharma Inc. Major Business
    Table 48. Astellas Pharma Inc. Anti-Dermatomycosis Treatment Product and Solutions
    Table 49. Astellas Pharma Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 50. Global Anti-Dermatomycosis Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
    Table 51. Global Anti-Dermatomycosis Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
    Table 52. Breakdown of Anti-Dermatomycosis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 53. Anti-Dermatomycosis Treatment Players Head Office, Products and Services Provided
    Table 54. Anti-Dermatomycosis Treatment Mergers & Acquisitions in the Past Five Years
    Table 55. Anti-Dermatomycosis Treatment New Entrants and Expansion Plans
    Table 56. Global Anti-Dermatomycosis Treatment Revenue (USD Million) by Drug Type (2017-2022)
    Table 57. Global Anti-Dermatomycosis Treatment Revenue Share by Drug Type (2017-2022)
    Table 58. Global Anti-Dermatomycosis Treatment Revenue Forecast by Drug Type (2023-2028)
    Table 59. Global Anti-Dermatomycosis Treatment Revenue by Application (2017-2022)
    Table 60. Global Anti-Dermatomycosis Treatment Revenue Forecast by Application (2023-2028)
    Table 61. North America Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2022) & (USD Million)
    Table 62. North America Anti-Dermatomycosis Treatment Revenue by Drug Type (2023-2028) & (USD Million)
    Table 63. North America Anti-Dermatomycosis Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 64. North America Anti-Dermatomycosis Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 65. North America Anti-Dermatomycosis Treatment Revenue by Country (2017-2022) & (USD Million)
    Table 66. North America Anti-Dermatomycosis Treatment Revenue by Country (2023-2028) & (USD Million)
    Table 67. Europe Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2022) & (USD Million)
    Table 68. Europe Anti-Dermatomycosis Treatment Revenue by Drug Type (2023-2028) & (USD Million)
    Table 69. Europe Anti-Dermatomycosis Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 70. Europe Anti-Dermatomycosis Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 71. Europe Anti-Dermatomycosis Treatment Revenue by Country (2017-2022) & (USD Million)
    Table 72. Europe Anti-Dermatomycosis Treatment Revenue by Country (2023-2028) & (USD Million)
    Table 73. Asia-Pacific Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2022) & (USD Million)
    Table 74. Asia-Pacific Anti-Dermatomycosis Treatment Revenue by Drug Type (2023-2028) & (USD Million)
    Table 75. Asia-Pacific Anti-Dermatomycosis Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 76. Asia-Pacific Anti-Dermatomycosis Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 77. Asia-Pacific Anti-Dermatomycosis Treatment Revenue by Region (2017-2022) & (USD Million)
    Table 78. Asia-Pacific Anti-Dermatomycosis Treatment Revenue by Region (2023-2028) & (USD Million)
    Table 79. South America Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2022) & (USD Million)
    Table 80. South America Anti-Dermatomycosis Treatment Revenue by Drug Type (2023-2028) & (USD Million)
    Table 81. South America Anti-Dermatomycosis Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 82. South America Anti-Dermatomycosis Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 83. South America Anti-Dermatomycosis Treatment Revenue by Country (2017-2022) & (USD Million)
    Table 84. South America Anti-Dermatomycosis Treatment Revenue by Country (2023-2028) & (USD Million)
    Table 85. Middle East & Africa Anti-Dermatomycosis Treatment Revenue by Drug Type (2017-2022) & (USD Million)
    Table 86. Middle East & Africa Anti-Dermatomycosis Treatment Revenue by Drug Type (2023-2028) & (USD Million)
    Table 87. Middle East & Africa Anti-Dermatomycosis Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 88. Middle East & Africa Anti-Dermatomycosis Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 89. Middle East & Africa Anti-Dermatomycosis Treatment Revenue by Country (2017-2022) & (USD Million)
    Table 90. Middle East & Africa Anti-Dermatomycosis Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
    Figure 1. Anti-Dermatomycosis Treatment Picture
    Figure 2. Global Anti-Dermatomycosis Treatment Revenue Market Share by Drug Type in 2021
    Figure 3. Polyens
    Figure 4. Azoles
    Figure 5. Allylamines
    Figure 6. Echinocandins
    Figure 7. Others
    Figure 8. Anti-Dermatomycosis Treatment Revenue Market Share by Application in 2021
    Figure 9. Tinea Corporis Picture
    Figure 10. Tinea Unguium Picture
    Figure 11. Aspergillosis Picture
    Figure 12. Tinea Capitis Picture
    Figure 13. Others Picture
    Figure 14. Global Anti-Dermatomycosis Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
    Figure 15. Global Anti-Dermatomycosis Treatment Revenue and Forecast (2017-2028) & (USD Million)
    Figure 16. Global Anti-Dermatomycosis Treatment Revenue Market Share by Region (2017-2028)
    Figure 17. Global Anti-Dermatomycosis Treatment Revenue Market Share by Region in 2021
    Figure 18. North America Anti-Dermatomycosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 19. Europe Anti-Dermatomycosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 20. Asia-Pacific Anti-Dermatomycosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 21. South America Anti-Dermatomycosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 22. Middle East and Africa Anti-Dermatomycosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 23. Anti-Dermatomycosis Treatment Market Drivers
    Figure 24. Anti-Dermatomycosis Treatment Market Restraints
    Figure 25. Anti-Dermatomycosis Treatment Market Trends
    Figure 26. Pfizer Inc. Recent Developments and Future Plans
    Figure 27. Sanofi S.A. Recent Developments and Future Plans
    Figure 28. Novatis AG Recent Developments and Future Plans
    Figure 29. Mylan N.V. Recent Developments and Future Plans
    Figure 30. Abbott Laboratories Recent Developments and Future Plans
    Figure 31. Bayer AG Recent Developments and Future Plans
    Figure 32. Scynexis Inc. Recent Developments and Future Plans
    Figure 33. Glaxosmithkline Plc Recent Developments and Future Plans
    Figure 34. Enzon Pharmaceuticals Recent Developments and Future Plans
    Figure 35. Gilead Sciences Inc. Recent Developments and Future Plans
    Figure 36. Astellas Pharma Inc. Recent Developments and Future Plans
    Figure 37. Global Anti-Dermatomycosis Treatment Revenue Share by Players in 2021
    Figure 38. Anti-Dermatomycosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
    Figure 39. Global Top 3 Players Anti-Dermatomycosis Treatment Revenue Market Share in 2021
    Figure 40. Global Top 10 Players Anti-Dermatomycosis Treatment Revenue Market Share in 2021
    Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
    Figure 42. Global Anti-Dermatomycosis Treatment Revenue Share by Drug Type in 2021
    Figure 43. Global Anti-Dermatomycosis Treatment Market Share Forecast by Drug Type (2023-2028)
    Figure 44. Global Anti-Dermatomycosis Treatment Revenue Share by Application in 2021
    Figure 45. Global Anti-Dermatomycosis Treatment Market Share Forecast by Application (2023-2028)
    Figure 46. North America Anti-Dermatomycosis Treatment Sales Market Share by Drug Type (2017-2028)
    Figure 47. North America Anti-Dermatomycosis Treatment Sales Market Share by Application (2017-2028)
    Figure 48. North America Anti-Dermatomycosis Treatment Revenue Market Share by Country (2017-2028)
    Figure 49. United States Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 50. Canada Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 51. Mexico Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 52. Europe Anti-Dermatomycosis Treatment Sales Market Share by Drug Type (2017-2028)
    Figure 53. Europe Anti-Dermatomycosis Treatment Sales Market Share by Application (2017-2028)
    Figure 54. Europe Anti-Dermatomycosis Treatment Revenue Market Share by Country (2017-2028)
    Figure 55. Germany Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 56. France Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 57. United Kingdom Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 58. Russia Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 59. Italy Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 60. Asia-Pacific Anti-Dermatomycosis Treatment Sales Market Share by Drug Type (2017-2028)
    Figure 61. Asia-Pacific Anti-Dermatomycosis Treatment Sales Market Share by Application (2017-2028)
    Figure 62. Asia-Pacific Anti-Dermatomycosis Treatment Revenue Market Share by Region (2017-2028)
    Figure 63. China Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 64. Japan Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 65. South Korea Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 66. India Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 67. Southeast Asia Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 68. Australia Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 69. South America Anti-Dermatomycosis Treatment Sales Market Share by Drug Type (2017-2028)
    Figure 70. South America Anti-Dermatomycosis Treatment Sales Market Share by Application (2017-2028)
    Figure 71. South America Anti-Dermatomycosis Treatment Revenue Market Share by Country (2017-2028)
    Figure 72. Brazil Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 73. Argentina Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 74. Middle East and Africa Anti-Dermatomycosis Treatment Sales Market Share by Drug Type (2017-2028)
    Figure 75. Middle East and Africa Anti-Dermatomycosis Treatment Sales Market Share by Application (2017-2028)
    Figure 76. Middle East and Africa Anti-Dermatomycosis Treatment Revenue Market Share by Country (2017-2028)
    Figure 77. Turkey Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 78. Saudi Arabia Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 79. UAE Anti-Dermatomycosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 80. Methodology
    Figure 81. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Pfizer Inc.
Sanofi S.A.
Novatis AG
Mylan N.V.
Abbott Laboratories
Bayer AG
Scynexis Inc.
Glaxosmithkline Plc
Enzon Pharmaceuticals
Gilead Sciences Inc.
Astellas Pharma Inc.

Product Tags

anti dermatomycosis treatment

Anti-Dermatomycosis Treatment

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>